BVNRY:OTCMKTS
Bavarian Nordic A/S - ADR
၁၁.၇၈ US$
arrow_downward
-၁.၅၄%(-၀.၁၈) 1D
အောက် ၁၃, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNRY...
Open
၁၁.၇၇ US$
High
၁၁.၇၈ US$
Low
၁၁.၇၇ US$
Mkt. cap
၂၈၂.၁၂ ဋေ
Avg. vol.
၃.၀၄ ထောင်
Volume
၈၉၅.၀၀
P/E ratio
၁၂.၇၀
52-wk high
၁၃.၀၀ US$
52-wk low
၈.၆၇ US$
EPS
၀.၉၃ US$
Beta
၁.၄၅
Shares outstanding
၂၃.၇၈ ကုဋေ
No. of employees
၂ ထောင်
Open
၁၁.၇၇ US$
High
၁၁.၇၈ US$
Low
၁၁.၇၇ US$
Mkt. cap
၂၈၂.၁၂ ဋေ
Avg. vol.
၃.၀၄ ထောင်
Volume
၈၉၅.၀၀
P/E ratio
၁၂.၇၀
52-wk high
၁၃.၀၀ US$
52-wk low
၈.၆၇ US$
EPS
၀.၉၃ US$
Beta
၁.၄၅
Shares outstanding
၂၃.၇၈ ကုဋေ
No. of employees
၂ ထောင်
News stories
From web sources and news partners
StockStory
·
ပြီးခဲ့သည့် ၁ မိနစ်
1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off
MarketBeat
·
ပြီးခဲ့သည့် ၂၅ မိနစ်
X-Energy (NASDAQ:XE) Reaches New 12-Month Low - Time to Sell?
Investor's Business Daily
·
ပြီးခဲ့သည့် ၃ မိနစ်
Dow Futures Rise; ASML Earnings Beat, CPI Inflation Due
Seeking Alpha
·
ပြီးခဲ့သည့် ၂ နာရီ
Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S - ADR